U.S., June 4 -- ClinicalTrials.gov registry received information related to the study (NCT07001904) titled 'Interleukin-6 in Plaque Psoriasis and Its Possible Role in Disease Severity' on May 24.
Brief Summary: This study aimed to evaluate serum IL-6 levels in plaque psoriasis patients and investigate their correlation with disease severity.
Study Start Date: Nov. 01, 2023
Study Type: OBSERVATIONAL
Condition:
Interleukin-6
Plaque Psoriasis
Disease Severity
Intervention:
OTHER: Enzyme-linked immunosorbent assay (ELISA)
The enzyme-linked immunosorbent assay (ELISA) was utilized in order to determine the levels of IL-6 in the serum
Recruitment Status: COMPLETED
Sponsor: Tanta University
Information provided by (Responsible Party): A...